CIENCIASMEDICASNEWS

Editorial Patient violence at the frontline of care The Lancet Primary Care ++ +...

Comparison of antidepressant deprescribing strategies in individuals with clinically remitted depression: a systematic review and network meta-analysis Debora Zaccoletti, PsyDa ∙ Carlotta Mosconi, MDa ∙ Chiara Gastaldon, PhDa ∙ Lorenzo Benedetti, MDa ∙ Carolina Gottardi, MDa ∙ Davide Papola, PhDa ∙ et al. https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(25)00330-X/abstract?utm_campaign=infocusalerts-psychiatry&utm_medium=email&dgcid=hubspot_email_infocusalerts-psychiatry_feature&_hsenc=p2ANqtz-9ZE0GRDHmMCRbjAGElqZnaArYX4W0Sd8CI9m1Ao3UbVvKACU91VU-OIdPb2Cx0DqsYDQks4D8eoQQCg47LIkP_KNUr0Q&_hsmi=404852086&utm_content=404691969&utm_source=hs_email Effectiveness of a guideline implementation tool for supporting management of mental health complications after mild traumatic brain injury versus usual care in primary care: a triple-blind, cluster-randomised controlled trial Ana Mikolić, PhDa,f,g ∙ Penelope M A Brasher, PhDh ∙ Linda C Li, PhDb ∙ Prof Jeffrey R Brubacher, MDc ∙ Frank X Scheuermeyer, MDc,i ∙ Pierre-Paul Lizotte, MDe ∙ et al. https://www.thelancet.com/journals/lanprc/article/PIIS3050-5143(25)00088-3/fulltext?dgcid=hubspot_email_infocusalerts-psychiatry_feature&utm_campaign=infocusalerts-psychiatry&utm_medium=email&_hsenc=p2ANqtz-_npr3Ej5zgzS-0KqbpPz02YY73xlRc-q0R2HJhSVs9CVl2yeE1oXhdh3-Mo1lIUDTEHaZEXb2MebC7eiGIxwlTKsH92A&_hsmi=404852086&utm_content=404691969&utm_source=hs_email Editorial Patient violence at the frontline of care The Lancet Primary Care https://www.thelancet.com/journals/lanprc/issue/vol2no1/PIIS3050-5143(26)X2001-5

The Lancet Healthy Longevity: looking to the future The Lancet Healthy Longevity ++... ++

The Lancet Healthy Longevity: looking to the future The Lancet Healthy Longevity https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(26)00005-X/fulltext?dgcid=raven_jbs_etoc_email Jan 2026 Volume 7Number 1 https://www.thelancet.com/journals/lanhl/issue/vol7no1/PIIS2666-7568(26)X2001-3 International trends and social disparities in pain of adults aged 50 years and older in 22 countries across Europe, Asia, and the Americas: a longitudinal population-based study Prof Esteban Calvo, PhDa,b,c esteban.calvo@umayor.cl ∙ Jose T Medina, MSa ∙ Hanna Grol-Prokopczyk, PhDd ∙ Prof Katherine Keyes, PhDe ∙ Prof Alvaro Castillo-Carniglia, PhDc,f ∙ Antonia Díaz-Valdés, PhDa ∙ et al https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(25)00127-8/fulltext?dgcid=raven_jbs_etoc_feature_lanhl Hypofractionated split-course versus standard radiotherapy in frail older patients with head and neck squamous-cell carcinoma (ELAN-RT trial): a non-inferiority, multicentre, open-label, randomised controlled trial Cécile Ortholan, MDa cecile.ortholan@chpg.mc ∙ Anne Aupérin, PhDb ∙ Prof Yungan Tao, MDc ∙ Sophie Renard, MDd ∙ Yoann Pointreau, MDe ∙ Cédrik Lafond, MDe ∙ et al. https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(25)00131-X/fulltext?dgcid=raven_jbs_etoc_feature_lanhl

Nature Medicine to investigate study that found cancer treatment is better in morning Sleuths point out inconsistencies in study that found big difference in timing of immunotherapy

https://www.statnews.com/2026/02/20/cancer-immunotherapy-morning-infusions-doubts-about-study/ By Angus ChenFeb. 20, 2026 Cancer Reporter

Gossamer lung disease drug fails late-stage study, but company will still seek FDA approval Despite the negative outcome, Gossamer believes seralutinib is effective in certain patients

https://www.statnews.com/2026/02/23/gossamer-drug-fails-lung-disease-study-will-still-seek-fda-approval/ By Adam FeuersteinFeb. 23, 2026 Senior Writer, Biotech

Women’s heart attack risk rises even if arteries aren’t as clogged as men’s Scans and risk calculators may miss lower levels of arterial plaque in women, study warns

https://www.statnews.com/2026/02/23/heart-disease-in-women-plaque-scan-risk/ By Elizabeth CooneyFeb. 23, 2026 Cardiovascular Disease Reporter

New approaches reveal how cancer drugs work in their cellular context Live-cell assays quantify the genetic and metabolic influence on drug selectivity, enabling the development of more precise cancer therapies.

https://www.drugdiscoverynews.com/new-approaches-reveal-how-cancer-drugs-work-in-their-cellular-context-16978 Oncology is increasingly shifting from broad-spectrum therapeutics to precision medicine strategies in an effort to create safer, more effective drugs. By tailoring treatments to the unique features of a patient’s tumor, researchers aim to exploit vulnerabilities that are invisible to traditional approaches. One compelling example of this principle at work is synthetic lethality, where specific mutation-driven weaknesses in cancer cells can be selectively targeted, allowing for precise and highly effective cell killing.